Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/45972
標題: Angiostrongylus cantonensis: Efficacy of albendazole-dexamethasone co-therapy against infection-induced plasminogen activators and eosinophilic meningitis
作者: Tu, W.C.
杜武俊
Lai, S.C.
關鍵字: tissue-type plasminogen activator;urokinase-type plasminogen activator;Angiostrongylus cantonensis;meningitis;dexamethasone;cerebrospinal-fluid;bacterial-meningitis;flow-rate;blood;mice;csf;meningoencephalitis;neurocysticercosis;immunoglobulins;praziquantel
Project: Experimental Parasitology
期刊/報告no:: Experimental Parasitology, Volume 113, Issue 1, Page(s) 8-15.
摘要: 
Angiostrongyliasis is one of the common causes leading to eosinophilic meningitis. Tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) may play a role in the pathogenesis. Administration of steroid drugs has been reported to possibly relieve the symptoms of eosinophilic meningitis. This study evaluates the curative effects of albendazole-dexamethasone co-therapy on eosinophilic meningitis in BALB/c mice. Assay indicators for the therapeutic effect include worm recovery, histopathological score of meningitis, tPA, uPA, total protein, and leukocyte counts. The results show that the albendazole-dexamethasone co-therapy significantly decreased (P < 0.05) these factors after treatment on day 5 post-inoculation (PI), in contrast to treatment on 15 PI. Thus, the timing of medication is important and is closely related to the anthelmintic efficacy of a drug. At the same dosage and days post-infection. the earlier administration shows better results. This study showed that albendazole-dexamethasone co-therapy is an effective approach for the treatment of parasitic meningitis. (c) 2005 Elsevier Inc. All rights reserved.
URI: http://hdl.handle.net/11455/45972
ISSN: 0014-4894
DOI: 10.1016/j.exppara.2005.11.017
Appears in Collections:昆蟲學系

Show full item record
 

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.